COMP <GO>
NNNN vs JNJ // PIOTROSKI F-SCORE QUALITY
Anbio Biotechnology (Class A) (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NNNN 3
— JNJ 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $3.36 (-9.68%) • MKT CAP: $535.3M
piotroski-score
5/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNNN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.20% | 67.90% | +19.30 | NNNN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.00% | 25.50% | -8.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.5x | 18.5x | +73.00 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | -1.26% | 2.97% | -4.23 | JNJ | /fcf-yield <GO> |
| Operating Margin | 66.70% | 34.70% | +32.00 | NNNN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | NNNN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | 6.00% | -0.40 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.9 | 62.1 | -24.20 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 77.7x | 23.0x | +54.70 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $535.3M | $662.49B | -$661.96B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNNN REV | JNJ REV | NNNN GROSS % | JNJ GROSS % | NNNN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.6M | $94.19B | 87.2% | 67.9% | -$6.7M | $19.70B |
| FY 2024 | $8.2M | $88.82B | 71.9% | 69.1% | $2.1M | $19.84B |
| FY 2023 | $6.7M | $85.16B | — | — | $898.4K | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
JNJ // BETA 1.08